Clinical Outcome of Adjuvant Treatment of Endometrial Cancer Using Aperture-Based Intensity-Modulated Radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 71, Issue 5, 2008, Pages 1343-1350

  Bouchard, Myriam ^a   Nadeau, Sylvain ^a,b   Gingras, Luc ^a,b   Raymond, Paul Émile ^a   Beaulieu, Frédéric ^a   Beaulieu, Luc ^a,b   Fortin, André ^a   Germain, Isabelle ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Aperture based intensity modulated radiotherapy; Disease control; Endometrial cancer; IMRT; Inverse planning; Toxicity

Indexed keywords

DISEASE CONTROL; ELECTROTHERAPEUTICS; PATIENT MONITORING; QUALITY ASSURANCE; RADIOTHERAPY; RISK ASSESSMENT; TOTAL QUALITY MANAGEMENT; TOXICITY;

ACUTE TOXICITIES; APERTURE-BASED INTENSITY-MODULATED RADIOTHERAPY; BEAMLET; BODY MASS INDEX; BRACHYTHERAPY; CHRONIC TOXICITIES; CLINICAL OUTCOME; CONTROL GROUP; ENDOMETRIAL CANCER; IMRT; INTENSITY-MODULATED RADIOTHERAPY; INVERSE PLANNING; ORGANS AT RISK; PELVIC IRRADIATION; PLANNING TARGET VOLUME; SECOND MALIGNANCY; TARGET COVERAGE; TREATMENT PLANNING SYSTEMS;

PHYSICAL THERAPY;

CONTRAST MEDIUM;

ADULT; AGED; ARTICLE; BODY MASS; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DOSIMETRY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HYSTERECTOMY; INTENSITY MODULATED RADIATION THERAPY; MORBIDITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT PLANNING; UROGENITAL TRACT DISEASE;

AGED; BONE MARROW; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; INTESTINES; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RADIATION DOSAGE; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, INTENSITY-MODULATED; RECTUM; TREATMENT OUTCOME; URINARY BLADDER;

EID: 47149099987     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.12.004     Document Type: Article

References (38)

1. Aalders J., Abeler V., Kolstad P., et al. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: Clinical and histopathologic study of 540 patients. Obstet Gynecol 56 (1980) 419-427
2. Sedlis A., Bundy B.N., Rotman M.Z., et al. A randomized trial of pelvic RT versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group study. Gynecol Oncol 73 (1999) 177-183
3. Creutzberg C.L., van Putten W.L., Koper P.C., et al., Post Operative RT in Endometrial Carcinoma (PORTEC) Study Group. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. Lancet 355 (2000) 1404-1411
4. Greer B.E., Koh W.J., Figge D.C., et al. Gynecologic radiotherapy fields defined by intraoperative measurements. Gynecol Oncol 38 (1990) 421-424
5. Bonin S.R., Lanciano R.M., Corn B.W., et al. Bony landmarks are not an adequate substitute for lymphangiography in defining pelvic lymph node location for the treatment of cervical cancer with radiotherapy. Int J Radiat Oncol Biol Phys 34 (1996) 167-172
6. Finlay M.H., Ackerman I., Tirona R.G., et al. Use of CT simulation for treatment of cervical cancer to assess the adequacy of lymph node coverage of conventional pelvic fields based on bony landmarks. Int J Radiat Oncol Biol Phys 64 (2006) 205-209
7. Portelance L., Chao K.S., Grigsby P.W., et al. IMRT reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys 51 (2001) 261-266
8. Mundt A.J., Roeske J.C., and Lujan A.E. IMRT in gynecologic malignancies. Med Dosim 27 (2002) 131-136
9. Lujan A.E., Mundt A.J., Yamada S.D., et al. IMRT as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 516-521
10. Heron D.E., Gerszten K., Selvaraj R.N., et al. Conventional 3D conformal versus IMRT for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of DVH. Gynecol Oncol 91 (2003) 39-45
11. Mundt A.J., Roeske J.C., Lujan A.E., et al. Initial clinical experience with intensity-modulated whole-pelvis RT in women with gynecologic malignancies. Gynecol Oncol 82 (2001) 456-463
12. Mundt A.J., Lujan A.E., Rotmensch J., et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 52 (2002) 1330-1337
13. Brixey C.J., Roeske J.C., Lujan A.E., et al. Impact of IMRT on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 54 (2002) 1388-1396
14. Salama J.K., Mundt A.J., Roeske J., et al. Preliminary outcome and toxicity report of extended-field, IMRT for gynecologic malignancies. Int J Radiat Oncol Biol Phys 65 (2006) 1170-1176
15. Mundt A.J., Mell L.K., and Roeske J.C. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic RT. Int J Radiat Oncol Biol Phys 56 (2003) 1354-1360
16. Jhingran A. Potential advantages of IMRT in gynecologic malignancies. Semin Radiat Oncol 16 (2006) 144-151
17. Randall M.E., and Ibbott G.S. IMRT for gynecologic cancers: Pitfalls, hazards, and cautions to be considered. Semin Radiat Oncol 16 (2006) 138-143
18. Wang J.Z., Li X.A., D'Souza W.D., et al. Impact of prolonged fraction delivery times on tumor control: A note of caution for IMRT. Int J Radiat Oncol Biol Phys 57 (2003) 543-552
19. Sterzing F., Munter M.W., Schafer M., et al. Radiobiological investigation of dose-rate effects in IMRT. Strahlenther Onkol 181 (2005) 42-48
20. Hall E.J. IMRT, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 65 (2006) 1-7
21. Hall E.J., and Wuu C.S. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56 (2003) 83-88
22. Beaulieu F., Beaulieu L., Tremblay D., et al. Simultaneous optimization of beam orientations, wedge filters and field weights for inverse planning with anatomy-based MLC fields. Med Phys 31 (2004) 1546-1557
23. Nadeau S., Bouchard M., Germain I., et al. Postoperative irradiation of gynecologic malignancies: Improving treatment delivery using AB-IMRT. Int J Radiat Oncol Biol Phys 68 (2007) 601-611
24. Georg P., Georg D., Hillbrand M., et al. Factors influencing bowel sparing in intensity modulated whole pelvic radiotherapy for gynaecological malignancies. Radiother Oncol 80 (2006) 19-26
25. Radiation Therapy Oncology Group. Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria. Available from: www.rtog.org. Accessed December 2004.
26. Greer B.E., Goff B.A., and Koh W.J. Endometrial carcinoma. In: Johnson F.E., and Virgo K. (Eds). Cancer patient follow-up (1997), Mosby, St-Louis 357-377
27. Lanciano R.M., Martz K., Montana G.S., et al. Influence of age, prior abdominal surgery, fraction size, and dose on complications after RT for squamous cell cancer of the uterine cervix: A patterns of care study. Cancer 69 (1992) 2124-2130
28. Bismar M.M., and Sinicrope F.A. Radiation enteritis. Curr Gastroenterol Rep 4 (2002) 361-365
29. Alektiar K.M. When and how should adjuvant radiation be used in early endometrial cancer?. Semin Radiat Oncol 16 (2006) 158-163
30. Small Jr. W., Erickson B., and Kwakwa F. ABS survey regarding practice patterns of postoperative irradiation for endometrial cancer: Current status of vaginal brachytherapy. Int J Radiat Oncol Biol Phys 63 (2005) 1502-1507
31. Beriwal S., Jain S.K., Heron D.E., et al. Clinical outcome with adjuvant treatment of endometrial carcinoma using IMRT. Gynecol Oncol 102 (2006) 195-199
32. Buchali A., Koswig S., Dinges S., et al. Impact of the filling status of the bladder and rectum on their integral dose distribution and the movement of the uterus in the treatment planning of gynaecologic cancer. Radiother Oncol 52 (1999) 29-34
33. Chao K.S., and Lin M. Lymphangiogram-assisted lymph node target delineation for patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys 54 (2002) 1147-1152
34. Roeske J.C., Lujan A., Rotmensch J., et al. Intensity-modulated whole pelvic RT in patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys 48 (2000) 1613-1621
35. Mundt AJ, Roeske J. Target and dose specification in gynecologic malignancies undergoing IMRT. Presented at the American Society for Therapeutic Radiology and Oncology 2003 Meeting, Salt Lake City, 2003.
36. Ahamad A., D'Souza W., Salehpour M., et al. IMRT after hysterectomy: Comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. Int J Radiat Oncol Biol Phys 62 (2005) 1117-1124
37. Taylor A., Rockall A.G., Reznek R.H., et al. Mapping pelvic lymph nodes: Guidelines for delineation in IMRT. Int J Radiat Oncol Biol Phys 63 (2005) 1604-1612
38. Hall E.J. Neutrons and carcinogenesis: A cautionary tale. Bull Cancer Radiother 83 (1996) 43s-46s